Literature DB >> 9436286

Expectant management as an option for men with stage T1c prostate cancer: a preliminary study.

J L Mohler1, B T Williams, J A Freeman.   

Abstract

The outcome of patients selecting observation of clinical stage T1c prostate cancer is unknown. A total of 101 men with clinical stage T1c prostate cancer were evaluated, counseled, and monitored in a standard fashion. Altogether, 27 men who elected observation were older and had greater co-morbidity but similar tumor characteristics as compared with 74 men who elected radical prostatectomy. In all, 9 men demonstrated clinical or biochemical evidence of progression after a mean follow-up of 23 months; 4 men who underwent radical prostatectomy had specimen-confined disease and undetectable post-operative levels of PSA. Observation appears to be a viable option for some men with clinical stage T1c prostate cancer.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9436286     DOI： 10.1007/bf01300184

Source DB:  PubMed          Journal:  World J Urol        ISSN： 0724-4983            Impact factor:   4.226


  30 in total

1.  Morphologic analysis of surgical margins with positive findings in prostatectomy for adenocarcinoma of the prostate.

Authors:  G E Voges; J E McNeal; E A Redwine; F S Freiha; T A Stamey
Journal:  Cancer       Date:  1992-01-15       Impact factor: 6.860

2.  The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus.

Authors:  M H Kaplan; A R Feinstein
Journal:  J Chronic Dis       Date:  1974-09

3.  Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging.

Authors:  D F Gleason; G T Mellinger
Journal:  J Urol       Date:  1974-01       Impact factor: 7.450

4.  High 10-year survival rate in patients with early, untreated prostatic cancer.

Authors:  J E Johansson; H O Adami; S O Andersson; R Bergström; L Holmberg; U B Krusemo
Journal:  JAMA       Date:  1992 Apr 22-29       Impact factor: 56.272

5.  Natural history of localised prostatic cancer. A population-based study in 223 untreated patients.

Authors:  J E Johansson; H O Adami; S O Andersson; R Bergström; U B Krusemo; W Kraaz
Journal:  Lancet       Date:  1989-04-15       Impact factor: 79.321

6.  Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease.

Authors:  M M Schapira; T L McAuliffe; A B Nattinger
Journal:  Med Care       Date:  1995-11       Impact factor: 2.983

7.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer.

Authors:  J I Epstein; P C Walsh; M Carmichael; C B Brendler
Journal:  JAMA       Date:  1994-02-02       Impact factor: 56.272

Review 8.  Recent results of management of palpable clinically localized prostate cancer.

Authors:  J Adolfsson; G Steineck; W F Whitmore
Journal:  Cancer       Date:  1993-07-15       Impact factor: 6.860

9.  Expectant management of localized prostatic cancer.

Authors:  W F Whitmore; J A Warner; I M Thompson
Journal:  Cancer       Date:  1991-02-15       Impact factor: 6.860

10.  The pathological features and prognosis of prostate cancer detectable with current diagnostic tests.

Authors:  M Ohori; T M Wheeler; J K Dunn; T A Stamey; P T Scardino
Journal:  J Urol       Date:  1994-11       Impact factor: 7.450
View more
  6 in total

Review 1.  Prostate cancer: a comprehensive review.

Authors:  S N Pentyala; J Lee; K Hsieh; W C Waltzer; A Trocchia; L Musacchia; M J Rebecchi; S A Khan
Journal:  Med Oncol       Date:  2000-05       Impact factor: 3.064

2.  Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols.

Authors:  C Shad Thaxton; Stacy Loeb; Kimberly A Roehl; Donghui Kan; William J Catalona
Journal:  Urology       Date:  2009-12-05       Impact factor: 2.649

Review 3.  Active surveillance or active treatment in localized prostate cancer?

Authors:  Lothar Weissbach; Jens Altwein
Journal:  Dtsch Arztebl Int       Date:  2009-05-29       Impact factor: 5.594

Review 4.  [Active surveillance for prostate cancer].

Authors:  M Graefen; S Ahyai; R Heuer; G Salomon; T Schlomm; H Isbarn; L Budäus; H Heinzer; H Huland
Journal:  Urologe A       Date:  2008-03       Impact factor: 0.639

Review 5.  Watchful waiting versus active surveillance: appropriate patient selection.

Authors:  Marc A Dall'Era; Christopher J Kane
Journal:  Curr Urol Rep       Date:  2008-05       Impact factor: 3.092

Review 6.  Continuing controversy over monitoring men with localized prostate cancer: a systematic review of programs in the prostate specific antigen era.

Authors:  Richard M Martin; David Gunnell; Freddie Hamdy; David Neal; Athene Lane; Jenny Donovan
Journal:  J Urol       Date:  2006-08       Impact factor: 7.450
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.